A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China
Latest Information Update: 22 May 2024
At a glance
- Drugs Crisugabalin (Primary)
- Indications Neuropathic pain
- Focus Registrational; Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 22 May 2024 New trial record